In Depth 14 Oct 2025 Prader Willi syndrome: five much-anticipated therapies poised for approval The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. October 14, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2025 First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? FDA approval for Stealth BioTherapeutics’ elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies? September 29, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Interview 15 Sep 2025 Tapping into the regulatory goldmine: Interview with Ruxandra Teslo The FDA is sitting on a data goldmine: CTds. These documents could help biotech navigate regulations, but how to make them public? September 15, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2025 With Lykos CRL now public, FDA opens new era of accountability As the release of a CRL declining Lykos’ therapy generates a strong reaction from MAPS, delve into what this new transparency could change. September 8, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2025 Oncolytic virus therapy for cancer: what’s been going on in 2025? This past year has seen various developments in the field of oncolytic virus therapies – in fundraising and in the clinic. August 1, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2025 Targeting orexin: the future of narcolepsy treatments There are a few new narcolepsy treatments being tested in the clinic, and recently, some of them have made promising strides. But how far along are they? July 30, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 16 Jul 2025 Eight rare autoimmune diseases biotechs are fighting to treat Discover eight rare autoimmune diseases you may not have heard of and what biotechs are doing to treat them. July 16, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 12 Mar 2025 Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field. March 12, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2025 Rare Disease Day: seven drugs awaiting approval in 2025 As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in 2025. February 28, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2025 Ten first-in-class drugs on track for FDA approval in 2025 As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval in 2025. January 16, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 17 Dec 2024 Ovarian cancer: BioNTech, Curelab, OvarianVax and more bring vaccines to the clinic A number of ovarian cancer vaccines are being evaluated including the world’s first cancer prevention vaccine, which recently received funding. December 17, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2024 Trump’s healthcare picks: Who they are and what they mean for the biopharma industry Trump’s nominees for top healthcare roles have sparked significant debate. So, what do their appointments signal for the future of healthcare in the U.S.? November 29, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email